Corrigendum to: Reported Incidence and Survival of Fallopian Tube Carcinomas: A Population-Based Analysis From the North American Association of Central Cancer Registries (Journal of the National Cancer Institute (2017) DOI: 10.1093/jnci/djx263);Reported incidence and survival of fallopian tube carcinomas: A population-based analysis from the North American Association of central cancer registries

Journal of the National Cancer Institute

Volumn 110, Issue 7, 2018, Pages 750-757

  Trabert, Britton ^a   Coburn, Sally B ^a   Mariani, Andrea ^b   Yang, Hannah P ^a   Rosenberg, Philip S ^a   Gierach, Gretchen L ^a   Wentzensen, Nicolas ^a   Cronin, Kathy A ^a   Sherman, Mark E ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CARCINOMA IN SITU; CAUSE SPECIFIC SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARY CARCINOMA; POPULATION; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TREND STUDY; UTERINE TUBE CARCINOMA;

EID: 85055417630     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djy078     Document Type: Erratum

References (33)

1. Piek JM, van Diest PJ, Zweemer RP, et al Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001; 195(4): 451-456.
2. Kurman RJ, Shih I. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol. 2011; 42(7): 918-931.
3. Crum CP, McKeon FD, Xian W. BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis. Int J Gynecol Cancer. 2012; 22: S29-S34.
4. Dubeau L, Drapkin R. Coming into focus: The nonovarian origins of ovarian cancer. Ann Oncol. 2013; 24: 28-35.
5. Bijron JG, Seldenrijk CA, Zweemer RP, et al Fallopian tube intraluminal tumor spread from noninvasive precursor lesions a novel metastatic route in early pelvic carcinogenesis. Am J Surg Pathol. 2013; 37(8): 1123-1130.
6. Sherman ME, Piedmonte M, Mai PL, et al Pathologic findings at risk-reducing salpingo-oophorectomy: Primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol. 2014; 32(29): 3275-3283.
7. Shaw PA, Rouzbahman M, Pizer ES, et al Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol. 2009; 22(9): 1133-1138.
8. Mingels MJ, Roelofsen T, van der Laak JA, et al. Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls. Gynecol Oncol. 2012; 127(1): 88-93.
9. Wethington SL, Park KJ, Soslow RA, et al Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC). Int J Gynecol Cancer. 2013; 23(9): 1603-1611.
10. Kindelberger DW, Lee Y, Miron A, et al Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007; 31(2): 161-169.
11. Roh MH, Kindelberger D, Crum CP Serous tubal intraepithelial carcinoma and the dominant ovarian mass: Clues to serous tumor origin? Am J Surg Pathol. 2009; 33(3): 376-383.
12. Tang SG, Onuma K, Deb P, et al Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: A study of 300 consecutive cases. Int J Gynecol Pathol. 2012; 31(2): 103-110.
13. Chen F, Gaitskell K, Garcia MJ, et al Serous tubal intraepithelial carcinomas associated with high-grade serous ovarian carcinomas: A systematic review. BJOG. 2017; 124(6): 872-878.
14. Powell CB. Risk reducing salpingo-oophorectomy for BRCA mutation carriers: Twenty years later. Gynecol Oncol. 2014; 132(2): 261-263.
15. Rabban JT, Garg K, Crawford B, et al Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery. Am J Surg Pathol. 2014; 38(6): 729-742.
16. Seidman JD, Krishnan J, Yemelyanova A, et al Incidental serous tubal intraepithelial carcinoma and non-neoplastic conditions of the fallopian tubes in grossly normal adnexa: A clinicopathologic study of 388 completely embedded cases. Int J Gynecol Pathol. 2016; 35(5): 423-429.
17. McCluggage WG, Hirschowitz L, Gilks CB, et al The fallopian tube origin and primary site assignment in extrauterine high-grade serous carcinoma: Findings of a survey of pathologists and clinicians. Int J Gynecol Pathol. 2017; 36(3): 230-239.
18. Stewart SL, Wike JM, Foster SL, et al The incidence of primary fallopian tube cancer in the United States. Gynecol Oncol. 2007; 107(3): 392-397.
19. Jemal A, Ward EM, Johnson CJ, et al Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J Natl Cancer Inst. 2017; 109(9): djx030.
20. Adamo MB, Johnson CH, Ruhl JL, Dickie LA, eds. 2012 SEER Program Coding and Staging Manual. National Cancer Institute, NIH. Publication number 12-5581. Bethesda, MD: US Department of Health and Human Services; 2012.
21. Howlader N, Ries LA, Mariotto AB, et al Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst. 2010; 102(20): 1584-1598.
22. Medeiros F, Muto MG, Lee Y, et al The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006; 30(2): 230-236.
23. Schneider S, Heikaus S, Harter P, et al Serous tubal intraepithelial carcinoma associated with extraovarian metastases. Int J Gynecol Cancer. 2017; 27(3): 444-451.
24. Gilks BC, Movahedi-Lankarani S, Baker PM, et al Protocol for the examination of specimens from patients with primary tumors of the ovary or fallopian tube. Northfield, IL: College of American Pathologists (CAP); 2014.
25. Singh N, Gilks CB, Hirschowitz L, et al Primary site assignment in tubo-ovarian high-grade serous carcinoma: Consensus statement on unifying practice worldwide. Gynecol Oncol. 2016; 141(2): 195-198.
26. Singh N, Gilks CB, Wilkinson N, et al The secondary Mullerian system, field effect, BRCA, and tubal fimbria: Our evolving understanding of the origin of tubo-ovarian high-grade serous carcinoma and why assignment of primary site matters. Pathology. 2015; 47(5): 423-431.
27. Committee on Gynecologic Practice. Committee opinion no. 620: Salpingectomy for ovarian cancer prevention. Obstet Gynecol. 2015; 125(1): 279-281.
28. Hicks-Courant KD. Growth in salpingectomy rates in the United States since 2000. Am J Obstet Gynecol. 2016; 215(5): 666-667.
29. Patrono MG, Iniesta MD, Malpica A, et al Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review. Gynecol Oncol. 2015; 139(3): 568-572.
30. Chay WY, McCluggage WG, Lee CH, et al Outcomes of incidental fallopian tube high-grade serous carcinoma and serous tubal intraepithelial carcinoma in women at low risk of hereditary breast and ovarian cancer. Int J Gynecol Cancer. 2016; 26(3): 431-436.
31. Eckert MA, Pan S, Hernandez KM, et al Genomics of ovarian cancer progression reveals diverse metastatic trajectories including intraepithelial metastasis to the fallopian tube. Cancer Discov. 2016; 6(12): 1342-1351.
32. Visvanathan K, Vang R, Shaw P, et al Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: A reproducibility study. Am J Surg Pathol. 2011; 35(12): 1766-1775.
33. Vang R, Visvanathan K, Gross A, et al Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol. 2012; 31(3): 243-253.